Abstract
Uridine diphosphate-glucuronosyltransferase (UGT)1 A 1,a key metabolizing enzyme for the anti-cancer agent irninotecan (CPT-11),has several gene polymorphisms,one of them UGT1A1 *28 .In the United States,genotyping for UGT1A1 *28 is carried out in the clinical setting but not yet in Japan.In the present study,to develop the basis of a new pharmaceutical service in this regard,we developed a genotyping analysis procedure for 4 polymorphisms of the UGT1A1 gene (UGT 1 A 1 *6 ,*27 ,*28 and *60 ).The direct sequence method was used in genotyping,and simplification was achieved through the use of commercially available kits,and outsourcing sequencing to 2 outside laboratories.The genotyping of each polymorphism of UGT1A1 was independently carried out by two pharmacists and the results for 16 patients were identical to those obtained by the outside laboratories.The genotyping of UGT1A1 *6 ,*27 ,*28 and *60 conducted using our system cost less and was completed in a shorter period of time than that done by the 2 outside laboratories.The system we developed will be the basis of a new pharmaceutical service that will help achieve personalized medication.
